Cargando…

Naltrexone/Bupropion extended release‐induced weight loss is independent of nausea in subjects without diabetes

Naltrexone/bupropion extended release (NB) is indicated as an adjunct to a reduced‐calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index of ≥30 or ≥27 kg m(−2) and ≥1 weight‐related comorbidity (e.g. hypertension, type 2 diabetes and dys...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hong, K., Herrmann, K., Dybala, C., Halseth, A. E., Lam, H., Foreyt, J. P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2016
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5129540/ https://www.ncbi.nlm.nih.gov/pubmed/27477337 http://dx.doi.org/10.1111/cob.12157

Ejemplares similares

Method‐of‐use study of naltrexone sustained release (SR)/bupropion SR on body weight in individuals with obesity
por: Halseth, Amy, et al.
Publicado: (2016)

Quality of life, binge eating and sexual function in participants treated for obesity with sustained release naltrexone/bupropion
por: Halseth, A., et al.
Publicado: (2018)

Naltrexone/Bupropion: Contrave®; Naltrexone SR/Bupropion SR
Publicado: (2012)

The relationship between early weight loss and weight loss maintenance with naltrexone-bupropion therapy
por: le Roux, Carel W., et al.
Publicado: (2022)

Naltrexone and Bupropion Combination Treatment for Smoking Cessation and Weight Loss in Patients With Schizophrenia
por: Lyu, Xuechan, et al.
Publicado: (2018)

Use of Contrave, Naltrexone with Bupropion, Bupropion, or Naltrexone and Major Adverse Cardiovascular Events: A Systematic Literature Review
por: Dahlberg, Sarah, et al.
Publicado: (2022)

Naltrexone sustained-release/bupropion sustained-release for the management of obesity: review of the data to date
por: Caixàs, Assumpta, et al.
Publicado: (2014)

Concurrent Improvement in Both Binge Eating and Depressive Symptoms with Naltrexone/Bupropion Therapy in Overweight or Obese Subjects with Major Depressive Disorder in an Open-Label, Uncontrolled Study
por: Guerdjikova, Anna I., et al.
Publicado: (2017)

Letter to the editor: naltrexone sustained-release/bupropion sustained-release for the management of obesity: review of the data to date
por: Buehler, Anna M
Publicado: (2015)

Effects of Naltrexone Sustained- Release/Bupropion Sustained-Release Combination Therapy on Body Weight and Glycemic Parameters in Overweight and Obese Patients With Type 2 Diabetes
por: Hollander, Priscilla, et al.
Publicado: (2013)

Extended-release naltrexone/bupropion is safe and effective among subjects with type 2 diabetes already taking incretin agents: a post-hoc analysis of the LIGHT trial
por: Wharton, Sean, et al.
Publicado: (2021)

Probing the Release of Bupropion and Naltrexone Hydrochloride Salts from Biopolymeric Matrices of Diverse Chemical Structures
por: Siamidi, Angeliki, et al.
Publicado: (2021)

Effect of combined naltrexone and bupropion therapy on the brain’s functional connectivity
por: Wang, Gene-Jack, et al.
Publicado: (2018)

Naltrexone HCI/bupropion HCI for chronic weight management in obese adults: patient selection and perspectives
por: Tek, Cenk
Publicado: (2016)

Effect of combined naltrexone and bupropion therapy on the brain's reactivity to food cues
por: Wang, G-J, et al.
Publicado: (2014)

Psychiatric adverse events and effects on mood with prolonged-release naltrexone/bupropion combination therapy: a pooled analysis
por: Pi-Sunyer, Xavier, et al.
Publicado: (2019)

Effects of topiramate, bupropion and naltrexone isolated or combined on subcutaneous adipose tissue in obese rats
por: Scudeler, Monica Alhadas, et al.
Publicado: (2022)

A Randomized, Phase 3 Trial of Naltrexone SR/Bupropion SR on Weight and Obesity-related Risk Factors (COR-II)
por: Apovian, Caroline M, et al.
Publicado: (2013)

Neural correlates of adherence to extended-release naltrexone pharmacotherapy in heroin dependence
por: Wang, A-L, et al.
Publicado: (2015)

Naltrexone extended-release injection: an option for the management of opioid abuse
por: Taylor, Robert, et al.
Publicado: (2011)

Mediterranean Diet and Naltrexone/Bupropion Treatment for Weight Loss in Overweight and Obese Breast Cancer Survivors and Non-Cancer Participants: A Pilot Randomized Controlled Trial
por: Cho, A-Ra, et al.
Publicado: (2020)

Role of Bupropion and Naltrexone in Managing Depression With Polycystic Ovary Syndrome: A Case Report and Literature Review
por: Shah, Kaushal, et al.
Publicado: (2020)

Successful naltrexone-bupropion treatment after several treatment failures in a patient with severe monogenic obesity
por: Welling, Mila S., et al.
Publicado: (2023)

Urinary Incontinence during Sleep Associated with Extended Release Form of Bupropion HCI
por: Izci, Filiz, et al.
Publicado: (2015)

Perceptions of extended-release naltrexone, methadone, and buprenorphine treatments following release from jail
por: Velasquez, Melissa, et al.
Publicado: (2019)

Patients’ experiences of continued treatment with extended-release naltrexone: a Norwegian qualitative study
por: Marciuch, Anne, et al.
Publicado: (2022)

Naltrexone/Bupropion Combination Therapy in Overweight or Obese Patients With Major Depressive Disorder: Results of a Pilot Study
por: McElroy, Susan L., et al.
Publicado: (2013)

Simultaneous determination of naltrexone and bupropion in their co-formulated tablet utilizing green chromatographic approach with application to human urine
por: Abdel-Gawad, Sherif A., et al.
Publicado: (2018)

Development of oral candidiasis following initiation and rechallenge of extended-release bupropion in a geriatric patient
por: Vadiei, Nina, et al.
Publicado: (2018)

Treating Opioid Dependence With Injectable Extended-Release Naltrexone (XR-NTX): Who Will Respond?
por: Nunes, Edward V., et al.
Publicado: (2015)

Factors associated with willingness to take extended release naltrexone among injection drug users
por: Ahamad, Keith, et al.
Publicado: (2015)

Dissolution Assay of Bupropion/Naltrexone Hydrochloride Salts of Bilayer Composition Tablets Following the Development and Validation of a Novel HPLC Method
por: Apostolidi, Anna, et al.
Publicado: (2022)

The Vivitrol pilot program (VPP): initial quantitative findings from an extended-release naltrexone study
por: Rieckmann, Traci, et al.
Publicado: (2015)

Medication Treatment for Opioid Use Disorders:: A Brief Overview with Comments on Extended Release Naltrexone
por: Woody, George
Publicado: (2017)

Personal recovery among people with opioid use disorder during treatment with extended-release naltrexone
por: Marciuch, Anne, et al.
Publicado: (2023)

Adaptation of a standard extended-release naltrexone (XR-NTX) protocol for rural re-entering offenders with OUD
por: Staton, Michele, et al.
Publicado: (2021)

Stereoselective Metabolism of Bupropion to OH-bupropion, Threohydrobupropion, Erythrohydrobupropion, and 4′-OH-bupropion in vitro
por: Sager, Jennifer E., et al.
Publicado: (2016)

Is psychosexual therapy a reliable alternative to bupropion extended-release to promote the sexual function in infertile women? An RCT
por: Pasha, Hajar, et al.
Publicado: (2020)

Estimating the impact of stimulant use on initiation of buprenorphine and extended-release naltrexone in two clinical trials and real-world populations
por: Cook, R. R., et al.
Publicado: (2023)

Effect of extended-release naltrexone on striatal dopamine transporter availability, depression and anhedonia in heroin-dependent patients
por: Zaaijer, Eline R., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_6rh4tpcp6vorbi247ckec7antq